Nav: Home

ACA credited with earlier diagnosis of gynecologic cancers in young women

July 11, 2018

The gains in insurance coverage with the Patient Protection and Affordable Care Act (ACA) have already translated into improved health for young women with gynecologic cancers, who are getting diagnosed at earlier stages of their disease because of ACA benefits. That's the conclusion of a new study by researchers at Johns Hopkins Medicine, who looked at nationwide trends in gynecologic cancer diagnosis in a large population of women before and after the ACA's implementation in 2010.

The results were published in the June issue of the journal Obstetrics & Gynecology.

"We were pleased to see that there was a significant improvement in capturing more women's cancers early," says Amanda Fader, M.D., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine and senior author of the new study. "It can take decades to observe changes in population-based health trends, so to see differences this soon is promising."

Women of all ages are at risk for gynecologic cancers, which include cervical, ovarian, uterine, vaginal and vulvar cancers. However, rates of these cancers--linked to both obesity and infection with human papilloma virus--are rising in young women. Each year in the U.S., about 2,000 women under the age of 26 are diagnosed with a gynecologic cancer. In this population, early diagnosis is critical to treatment success and the ability to maintain fertility after treatment, Fader notes.

Fader and her team credit the ACA for the improvement in early diagnosis because one of the key parts of the health care law was the dependent coverage mandate, which allows young adults to stay on their parent's health insurance through age 26. Nationwide, before the ACA, one in three women aged 19-26 were uninsured; since the new health care legislation went into effect, less than one in five of these women are uninsured.

"We know if these women are identified early and treated early, they are much more likely to live longer and have their cancer go into remission," says Anna Jo Bodurtha Smith, M.D., M.P.H., a gynecology and obstetrics resident at the Johns Hopkins University School of Medicine and first author of the new paper.

For the study, Fader and Smith looked at data from the National Cancer Database of women aged 21-26 compared with women aged 27-35 who were diagnosed with a gynecologic cancer either between 2004 and 2009, before the ACA was enacted, or between 2011 and 2014, after the health care law was in force. The database collects patient data from 1,500 cancer programs around the U.S., including from The Johns Hopkins Hospital, and is thought to include more than 70 percent of all new cancer diagnoses in the country.

The researchers analyzed how insurance coverage was associated with stage at cancer diagnosis and receipt of fertility-sparing treatment. They also adjusted for demographic factors that may affect access to health care including race, household income and education level.

A total of 1,912 gynecologic cancers pre-ACA and 2,059 post-ACA were identified in women 21-26 years old; in women 27-35 years old, 9,782 cases were identified in the pre-ACA time period and 10,456 post-ACA.

When the researchers compared these numbers, and adjusted the numbers for potentially confounding factors such as education and income, they found a significant decrease in rates of uninsurance and a significant increase in early-stage diagnosis in the younger group of women but not the older group of women. Before the ACA, 56.2 percent of women aged 21-26 years old were diagnosed at an early stage of their cancer; after the ACA, 61.2 percent were diagnosed at an early stage. Early stage diagnosis did not significantly change in women aged 27-35, the comparison group. However, receipt of fertility-sparing treatment increased for women in both age groups, from 38.2 to 43.2 percent in women aged 21-26 and from 17.6 to 20.6 percent in women aged 27-35.

"As the debate on how we insure women goes on, reminding ourselves that these insurance gains have huge impacts on people's lives is the big takeaway here," says Smith.

While the results of this study shed light on the need for continued access to insurance coverage, especially among young women, the researchers caution that the numbers must be followed over a longer period of time to fully understand them. Since a relatively small number of women are diagnosed with gynecologic cancers each year, the power of the study to detect differences between groups was limited.

While adoption of the ACA dependent care mandate led to a 2.5 to 2.8 percent increase in premiums for health insurance plans that cover children, relative to single-coverage plans, it's estimated that early deaths from gynecologic cancer cost the U.S. economy more than $2 billion annually.

The cost of treatment for each case of cervical cancer, the main type of gynecologic cancer among young women, ranges from $25,000 to more than $500,000, with a higher cost associated with the surgery, chemotherapy and radiotherapy needed for advanced cases. Identifying women with cervical cancer at early stages could save millions of dollars annually--and help women have less toxic treatments and enable them to keep working.

"Detecting and treating cancer at an early stage saves lives and absolutely lowers health care costs compared to treatment of cancer at a more advanced, incurable stage," Fader said. "Survival rates improve dramatically when precancer or cancer is identified when the disease is confined to the organ of origin. The cancer is much more likely to be treated successfully, and in the case of reproductive cancers, the potential to preserve fertility and the option of having children can be realized for more women."

Fader and Smith plan to continue studying how diagnostic trends change over time, and look in more detail at subgroups of women at highest risk of developing gynecologic cancers. In the future, they say they hope to study whether the ACA, or other policy changes, can influence not only the diagnosis of gynecologic cancers, but also the prevalence of the cancers.
The study was funded internally and the authors have no financial relationships relevant to the article.

Johns Hopkins Medicine

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...